# VAV2

## Overview
VAV2 is a gene that encodes the vav guanine nucleotide exchange factor 2, a protein that functions as a guanine nucleotide exchange factor (GEF) primarily involved in the activation of Rho family GTPases. These GTPases, including Rac1, Cdc42, and RhoA, are critical for the regulation of the actin cytoskeleton and various cell signaling pathways, influencing processes such as cell migration, proliferation, and morphology (Abe2000Vav2; Liu2000Vav2). The VAV2 protein is characterized by several functional domains, including a Dbl homology (DH) domain, a pleckstrin homology (PH) domain, and a Src homology 2 (SH2) domain, which facilitate its interactions with other proteins and its localization to cellular membranes (Abe2000Vav2; Wu2012Identification). VAV2 is activated by tyrosine phosphorylation in response to growth factors, playing a pivotal role in cellular responses such as chemotactic migration and endothelial cell function (Garrett2007VEGFinduced). Alterations in the VAV2 gene have been associated with various diseases, including cancer and glaucoma, highlighting its clinical significance in human health (Fujikawa2010VAV2; Lorenzo-Martín2020VAV2).

## Structure
The VAV2 protein is a guanine nucleotide exchange factor (GEF) that plays a crucial role in activating Rho family GTPases. Its molecular structure includes several domains that contribute to its function. The Dbl homology (DH) domain is responsible for the GTPase binding and catalytic activity, facilitating nucleotide exchange (Abe2000Vav2; Wu2012Identification). The pleckstrin homology (PH) domain is essential for membrane localization and modulating the DH domain's function, particularly in Vav2, where it is crucial for activity (Marignani2001Vav2; Booden2002Critical). The cysteine-rich domain (CRD) is also important for membrane association and catalytic activity (Booden2002Critical).

VAV2 contains a calponin homology (CH) domain, an acidic region, a zinc finger (ZF) domain, a Src homology 2 (SH2) domain, and two Src homology 3 (SH3) domains, which are involved in protein-protein interactions (Wu2012Identification). The SH2 domain specifically recognizes phosphotyrosine motifs and interacts with phosphorylated receptors and adaptor proteins (Wu2012Identification). Post-translational modifications, such as phosphorylation, regulate VAV2's activity, particularly through the SH2 domain (Wu2012Identification). The protein may exist in different isoforms due to alternative splicing, although specific details on these isoforms are not provided in the context.

## Function
VAV2 is a guanine nucleotide exchange factor (GEF) that primarily activates Rho family GTPases, including Rac1, Cdc42, and RhoA, which are crucial for the organization of the actin cytoskeleton and cell signaling pathways (Abe2000Vav2; Liu2000Vav2). In healthy human cells, VAV2 is activated by tyrosine phosphorylation in response to growth factors such as epidermal growth factor (EGF) and platelet-derived growth factor (PDGF), but not by integrin-mediated adhesion (Liu2000Vav2). This activation leads to changes in cell morphology, including membrane ruffling and lamellipodia formation, which are essential for cell motility and proliferation (Abe2000Vav2; Liu2000Vav2).

VAV2 is also involved in the regulation of Rac1 activity, which is important for actin cytoskeleton reorganization and cellular responses such as cell migration (Tamás2003Mechanism). In endothelial cells, VAV2 is crucial for VEGF-induced Rac1 activation, which is necessary for cell migration, highlighting its role in chemotactic migration and endothelial cell function (Garrett2007VEGFinduced). VAV2's activity is regulated by its interaction with specific domains and is dependent on Src kinase activity (Marignani2001Vav2).

## Clinical Significance
Mutations and alterations in the VAV2 gene have been implicated in several diseases. In head and neck squamous cell carcinoma (hnSCC), VAV2 is overexpressed and linked to tumorigenic and metastatic properties. This overexpression is associated with a stem cell-like gene expression program, which correlates with poor prognosis in patients, particularly those who are human papillomavirus-negative (LorenzoMartín2020Drug; Lorenzo-Martín2020VAV2). VAV2 is also involved in the development of familial oral squamous cell carcinomas, where mutations such as V872I can alter protein function and promote tumorigenesis (Huang2019Identification).

In the context of glaucoma, VAV2 mutations are linked to elevated intraocular pressure and retinal ganglion cell loss, contributing to the disease's pathogenesis. VAV2 and VAV3 have been identified as candidate genes for primary open-angle glaucoma, particularly in Japanese populations (Fujikawa2010VAV2).

VAV2 polymorphisms are also associated with cardiovascular risk factors. The rs602990 polymorphism is linked to increased risk of target organ damage and obesity, as well as alterations in blood pressure and retinal artery caliber (PerrettaTejedor2017Association). These findings suggest that VAV2 plays a significant role in various pathological conditions through its influence on cellular signaling pathways.

## Interactions
VAV2 is a guanine nucleotide exchange factor that interacts with various proteins, playing a significant role in cellular signaling pathways. It interacts with the small GTPase Rac1, facilitating processes such as cell migration and neuronal development (Wu2012Identification). VAV2 also binds to the amyloid precursor protein (APP) through its SH2 domain, specifically recognizing the Y682-phosphorylated site on APP. This interaction is crucial for regulating APP levels and its cleavage products, which are relevant in Alzheimer's disease and cancer (Zhang2022Vav2).

VAV2 interacts with Arap3, a dual GTPase-activating protein for RhoA and Arf6. This interaction is mediated by the SH2 domain of VAV2 binding to phosphorylated tyrosine residues Y1403 and Y1408 on Arap3, facilitating VAV2's recruitment to the plasma membrane (Wu2012Identification). VAV2 also associates with hSiah2, a protein that inhibits VAV2-mediated signaling pathways. This interaction occurs in the cytoplasm and does not depend on VAV2's tyrosine phosphorylation (Germani1999hSiah2).

In T cell signaling, VAV2 interacts with phosphorylated forms of SLP-76, supporting its recruitment into microclusters. It also interacts with multiple Rho family GTPases, including Rac1, Rac2, and Cdc42, influencing calcium signaling and T cell activation (Fray2020Vav2).


## References


[1. (Wu2012Identification) Bo Wu, Fengsong Wang, Jiahai Zhang, Zhiyong Zhang, Liying Qin, Junhui Peng, Fudong Li, Jianping Liu, Guowei Lu, Qingguo Gong, Xuebiao Yao, Jihui Wu, and Yunyu Shi. Identification and structural basis for a novel interaction between vav2 and arap3. Journal of Structural Biology, 180(1):84–95, October 2012. URL: http://dx.doi.org/10.1016/j.jsb.2012.06.011, doi:10.1016/j.jsb.2012.06.011. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.jsb.2012.06.011)

[2. (Zhang2022Vav2) Youjia Zhang, Xiaxin Yang, Yongrui Liu, Liang Ge, Jiarong Wang, Xiulian Sun, Bo Wu, and Junfeng Wang. Vav2 is a novel app-interacting protein that regulates app protein level. Scientific Reports, July 2022. URL: http://dx.doi.org/10.1038/s41598-022-16883-z, doi:10.1038/s41598-022-16883-z. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-022-16883-z)

[3. (Garrett2007VEGFinduced) Tiana A. Garrett, Jaap D. Van Buul, and Keith Burridge. Vegf-induced rac1 activation in endothelial cells is regulated by the guanine nucleotide exchange factor vav2. Experimental Cell Research, 313(15):3285–3297, September 2007. URL: http://dx.doi.org/10.1016/j.yexcr.2007.05.027, doi:10.1016/j.yexcr.2007.05.027. This article has 135 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.yexcr.2007.05.027)

[4. (Tamás2003Mechanism) Péter Tamás, Zita Solti, Petra Bauer, András Illés, Szabolcs Sipeki, András Bauer, Anna Faragó, Julian Downward, and László Buday. Mechanism of epidermal growth factor regulation of vav2, a guanine nucleotide exchange factor for rac. Journal of Biological Chemistry, 278(7):5163–5171, February 2003. URL: http://dx.doi.org/10.1074/jbc.m207555200, doi:10.1074/jbc.m207555200. This article has 97 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m207555200)

[5. (Fray2020Vav2) Michael A. Fray, John C. Charpentier, Nicholas R. Sylvain, Maria-Cristina Seminario, and Stephen C. Bunnell. Vav2 lacks ca2+ entry-promoting scaffolding functions unique to vav1 and inhibits t cell activation via cdc42. Journal of Cell Science, March 2020. URL: http://dx.doi.org/10.1242/jcs.238337, doi:10.1242/jcs.238337. This article has 7 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1242/jcs.238337)

[6. (Liu2000Vav2) Betty P. Liu and Keith Burridge. Vav2 activates rac1, cdc42, and rhoa downstream from growth factor receptors but not β1 integrins. Molecular and Cellular Biology, 20(19):7160–7169, October 2000. URL: http://dx.doi.org/10.1128/mcb.20.19.7160-7169.2000, doi:10.1128/mcb.20.19.7160-7169.2000. This article has 170 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.20.19.7160-7169.2000)

[7. (Fujikawa2010VAV2) Keiko Fujikawa, Takeshi Iwata, Kaoru Inoue, Masakazu Akahori, Hanako Kadotani, Masahiro Fukaya, Masahiko Watanabe, Qing Chang, Edward M. Barnett, and Wojciech Swat. Vav2 and vav3 as candidate disease genes for spontaneous glaucoma in mice and humans. PLoS ONE, 5(2):e9050, February 2010. URL: http://dx.doi.org/10.1371/journal.pone.0009050, doi:10.1371/journal.pone.0009050. This article has 43 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0009050)

[8. (Germani1999hSiah2) Antonia Germani, Francisco Romero, Martin Houlard, Jacques Camonis, Sylvie Gisselbrecht, Siegmund Fischer, and Nadine Varin-Blank. Hsiah2 is a new vav binding protein which inhibits vav-mediated signaling pathways. Molecular and Cellular Biology, 19(5):3798–3807, May 1999. URL: http://dx.doi.org/10.1128/mcb.19.5.3798, doi:10.1128/mcb.19.5.3798. This article has 33 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.19.5.3798)

[9. (LorenzoMartín2020Drug) Luis Francisco Lorenzo-Martín, Mauricio Menacho-Márquez, and Xosé R. Bustelo. Drug vulnerabilities and disease prognosis linked to the stem cell-like gene expression program triggered by the rho gtpase activator vav2 in hyperplastic keratinocytes and head and neck cancer. Cancers, 12(9):2498, September 2020. URL: http://dx.doi.org/10.3390/cancers12092498, doi:10.3390/cancers12092498. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers12092498)

[10. (PerrettaTejedor2017Association) Nuria Perretta-Tejedor, Javier Fernández-Mateos, Luis García-Ortiz, Manuel A. Gómez-Marcos, José I. Recio-Rodríguez, Cristina Agudo-Conde, Emiliano Rodriguez-Sánchez, Ana I. Morales, Francisco J. López-Hernández, José M. López-Novoa, Rogelio González-Sarmiento, and Carlos Martínez-Salgado. Association of vav2 and vav3 polymorphisms with cardiovascular risk factors. Scientific Reports, February 2017. URL: http://dx.doi.org/10.1038/srep41875, doi:10.1038/srep41875. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/srep41875)

[11. (Abe2000Vav2) Karon Abe, Kent L. Rossman, Betty Liu, Kimberly D. Ritola, Derek Chiang, Sharon L. Campbell, Keith Burridge, and Channing J. Der. Vav2 is an activator of cdc42, rac1, and rhoa. Journal of Biological Chemistry, 275(14):10141–10149, April 2000. URL: http://dx.doi.org/10.1074/jbc.275.14.10141, doi:10.1074/jbc.275.14.10141. This article has 216 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.275.14.10141)

[12. (Marignani2001Vav2) Paola A. Marignani and Christopher L. Carpenter. Vav2 is required for cell spreading. The Journal of Cell Biology, 154(1):177–186, July 2001. URL: http://dx.doi.org/10.1083/jcb.200103134, doi:10.1083/jcb.200103134. This article has 85 citations.](https://doi.org/10.1083/jcb.200103134)

[13. (Huang2019Identification) Yaping Huang, Jizhi Zhao, Guogen Mao, Grace Sanghee Lee, Jia Zhang, Lijun Bi, Liya Gu, Zhijie Chang, Joseph Valentino, and Guo-Min Li. Identification of novel genetic variants predisposing to familial oral squamous cell carcinomas. Cell Discovery, November 2019. URL: http://dx.doi.org/10.1038/s41421-019-0126-6, doi:10.1038/s41421-019-0126-6. This article has 19 citations.](https://doi.org/10.1038/s41421-019-0126-6)

[14. (Lorenzo-Martín2020VAV2) L. Francisco Lorenzo-Martín, Natalia Fernández-Parejo, Mauricio Menacho-Márquez, Sonia Rodríguez-Fdez, Javier Robles-Valero, Sonia Zumalave, Salvatore Fabbiano, Gloria Pascual, Juana M. García-Pedrero, Antonio Abad, María C. García-Macías, Nazareno González, Pablo Lorenzano-Menna, Miguel A. Pavón, Rogelio González-Sarmiento, Carmen Segrelles, Jesús M. Paramio, José M. C. Tubío, Juan P. Rodrigo, Salvador A. Benitah, Myriam Cuadrado, and Xosé R. Bustelo. Vav2 signaling promotes regenerative proliferation in both cutaneous and head and neck squamous cell carcinoma. Nature Communications, September 2020. URL: http://dx.doi.org/10.1038/s41467-020-18524-3, doi:10.1038/s41467-020-18524-3. This article has 35 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-020-18524-3)

[15. (Booden2002Critical) Michelle A. Booden, Sharon L. Campbell, and Channing J. Der. Critical but distinct roles for the pleckstrin homology and cysteine-rich domains as positive modulators of vav2 signaling and transformation. Molecular and Cellular Biology, 22(8):2487–2497, April 2002. URL: http://dx.doi.org/10.1128/mcb.22.8.2487-2497.2002, doi:10.1128/mcb.22.8.2487-2497.2002. This article has 38 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.22.8.2487-2497.2002)